Abstract

In this manuscript, we compare the expectations versus the real word results and handling of three repurposed COVID-19 drugs; tocilizumab, remdesivir and favipiravir providing a personal perspective to affiliate a well-known metaphor to describe their outcomes; the good, the bad and the ugly, respectively and encouraging those colleagues who consider these drugs in their COVID-19 management to consider the risk benefit ratio accordingly.